ClinicalTrials.gg
CompletedNCT02087059Updated Jul 11, 2016Results posted

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

A Phase 3 interventional study of Ruxolitinib in Primary Myelofibrosis (MF), sponsored by Novartis Pharmaceuticals. Completed at 29 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.

Enrollment
19th of 50
51 · median 45
Started
2014
with 2 others
Phase 3
6 of 50
none open now
Registered
20th of 50
by date
Lead sponsor
11 of 50
Novartis Pharmaceuticals

Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 19th largest by enrollment, is one of 3 that started in 2014, is one of 6 in phase 3, and was the 20th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing ruxolitinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This is an open-label, multicenter clinical study in order to collect and examine data concerning the safety and efficacy of ruxolitinib in patients with Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Post-Essential Thrombocythemia (ET) MF.

03

Conditions studied

  • Primary Myelofibrosis (MF)

Browse trials for

Keywords

  • Post-Polycythemia Vera (PV) MF
  • Post-Essential Thrombocythemia (ET) MF
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years of age
  2. Diagnosis of PMF, PPV-MF, or PET-MF, regardless of JAK2 mutational status. The diagnostic of PMF will be according to the World Health Organization (WHO) criteria (Thiele et al., 2008) and PPV-MF and PET-MF according to the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria (Barosi et al., 2008).
  3. At least one risk factors provided in the definition of IWG-MRT (Cervantes et al., 2009; classified as intermediate risk-1, intermediate risk-2, or high risk)
  4. Patients with intermediate risk-1 (patients who have only one of the IMG-MRT risk factors indicated above ) must have palpable splenomegaly with a length of ≥5 cm from the costal margin to the point of the greatest spleen protrusion.
  5. Proportion of blasts in peripheral blood \<10%
  6. performance status of 0 to 2
  7. The following values for bone marrow function prior to treatment:

    1. ≥1,000/μL, and
    2. count ≥50,000/μL without administration of a growth factor, thrombopoietin, or platelet transfusion
  8. Stem cell transplantation is not a treatment option at present because it is not indicated or because there are no suitable donors.
  9. All drugs used to treat MF were discontinued at least 28 days before treatment initiation.
  10. form should be signed before any screening procedures is performed

Exclusion criteria

Exclusion Criteria:

  1. Hepatic or renal impairment as indicated by the following:

    • Direct ≥2-fold than the (ULN)
    • (ALT) >2.5-fold ULN
    • Creatinine >2.0 mg/dL
  2. infection by bacteria, fungus, mycobacteria, parasite, or virus (screening and enrollment postponed until completion of antibiotic treatment in patients with an acute bacterial infection that requires antibiotic use)
  3. Active hepatitis A, B, or C or infection defined by a positive IgM-HA Ab test [hepatitis A virus antibody (immunoglobulin M [IgM])], HBs Ag test ( surface antigen), Ab test (hepatitis C virus antibody), or HIV Ab (human immunodeficiency virus antibody) at screening.
  4. History of within the previous 3 years, except for early-stage squamous cell carcinoma and basal cell carcinoma.
  5. History of serious congenital or acquired hemorrhagic disease
  6. Previous count \<25,000/μL or \<500/μL, except for patients currently undergoing treatment for a myeloproliferative neoplasm or cytotoxic therapy for any other reason.
  7. Splenic irradiation within 12 months before screening
  8. Administration of hematopoietic growth factor receptor agonists (erythropoietin, granulocyte colony stimulating factor, romiplostim, eltrombopag) within 14 days before screening or 28 days before treatment initiation.
  9. Currently receiving another drug, or received another investigational drug within 30 days before the start of treatment.
  10. History of myocardial infarction or acute coronary syndrome within 6 months before screening
  11. Poorly controlled or unstable angina at present
  12. Rapid or paroxysmal atrial fibrillation at present
  13. Active alcohol or drug addiction that could hinder the patient's ability to comply with the study's requirements
  14. Pregnant or currently breastfeeding woman
  15. Women of or men with reproductive ability who are unwilling to take appropriate measures
  16. Patient with any concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol
  17. History of to the study drug or a drug with a similar chemical structure
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Ruxolitinib

    Ruxolitinib was administered orally twice daily at the starting dose of 5 mg, 15 mg or 20 mg bid based on Baseline platelet counts. The dosage was subsequently adjusted for safety and efficacy so that each patient was titrated to their most appropriate dose.

    Drug: Ruxolitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    Time frame: 24 weeks

Secondary outcomes

  1. Charge in Spleen Size From Baseline at Specified Week

    Number of patients with spleen length reduced by ≥ 50% at specified week

    Time frame: Baseline, 24 weeks

  2. Charge in Spleen Size From Baseline up to the Specified Week

    Number of patients with spleen length reduced by ≥ 50% up to specified week

    Time frame: Baseline, 24 weeks

  3. Summary of Total Symptom Score as Measured by Seven-day Modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 by Time

    The modified MFSAF v2.0 diary captures a patient's symptom severity on a scale of 0 (absent) to 10 (worst imaginable),with a maximal summary score of 60

    Time frame: 24 weeks

  4. Summary of Summary of EORTC QLQ-C30 Responses by Time

    The QLQ-C30 version 1.0 (QLQ-C30) incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhea) and perceived financial impact of the disease.All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: 24 weeks

07

Results

Posted Jul 11, 2016

Participant flow

Participant flow — Overall Study
MilestoneRuxolitinib
Started51
Completed44
Not completed7
Withdrew: Disease progression1
Withdrew: Adverse event5
Withdrew: Lost to follow-up1

Outcome measures

PrimaryNumber of Participants With Adverse Events as a Measure of Safety and Tolerability
Time frame:
24 weeks
Reported as:
Number · Participants
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
ParticipantsRuxolitinib
AEs, regardless of study treatment relationship50
AEs suspected to be related to study treatment46
SAEs, regardless of study treatment relationship12
SAEs suspected to be related to study treatment5
AEs of CTC grade 3/4, regardless study treatment36
AEs of CTC grade 3/4 suspected related treatment33
AEs leading to the study treatment discontinuation5
AEs requiring reduction or interruption treatment38
AEs requiring concomitant medication33
SecondaryCharge in Spleen Size From Baseline at Specified Week

Number of patients with spleen length reduced by ≥ 50% at specified week

Time frame:
Baseline, 24 weeks
Reported as:
Number · particiapants
Charge in Spleen Size From Baseline at Specified Week
particiapantsRuxolitinib
Week 212
Week 414
Week 814
Week 1211
Week 1614
Week 2013
Week 2415
SecondaryCharge in Spleen Size From Baseline up to the Specified Week

Number of patients with spleen length reduced by ≥ 50% up to specified week

Time frame:
Baseline, 24 weeks
Reported as:
Number · particiapants
Charge in Spleen Size From Baseline up to the Specified Week
particiapantsRuxolitinib
Week 418 (13.1 to 38.2)
Week 822 (16.2 to 42.5)
Week 1223 (16.2 to 42.5)
Week 1626
Week 2026
Week 2426
SecondarySummary of Total Symptom Score as Measured by Seven-day Modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 by Time

The modified MFSAF v2.0 diary captures a patient's symptom severity on a scale of 0 (absent) to 10 (worst imaginable),with a maximal summary score of 60

Time frame:
24 weeks
Reported as:
Mean · score on a scale
Summary of Total Symptom Score as Measured by Seven-day Modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 by Time
score on a scaleRuxolitinib
Night Sweats baseline (n=51)2.9 ± 3.07
Night Sweats week 24 (n=43)0.6 ± 1.35
Itching baseline (n=51)1.8 ± 2.39
Itching week 24 (n=430.6 ± 1.25
Abdominal Discomfort baseline( n=51)4.4 ± 3.18
Abdominal Discomfort week 24(n=43)1.4 ± 1.84
Pain under ribs on left Baseline (=51)2.2 ± 2.72
Pain under ribs on left week 24 (=43)0.7 ± 1.26
Feeling of fullness Baseline (n=51)3.2 ± 2.91
Feeling of fullness week 24 (n=43)1.3 ± 1.8
Bone/muscle pain Baseline (n=51)2.3 ± 2.83
Bone/muscle pain week 24 (n=43)1.0 ± 1.83
Degree of inactivity Baseline (n=51)2.3 ± 2.84
Degree of inactivity week 24 (n=43)1.0 ± 1.66
Total symptom score baseline (n=51)16.8 ± 12.30
Total symptom score week 24 (n=43)5.7 ± 6.48
SecondarySummary of Summary of EORTC QLQ-C30 Responses by Time

The QLQ-C30 version 1.0 (QLQ-C30) incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhea) and perceived financial impact of the disease.All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

Time frame:
24 weeks
Reported as:
Mean · units on a scale
Summary of Summary of EORTC QLQ-C30 Responses by Time
units on a scaleRuxolitinib
Physical Functioning baseline79.35 ± 17.951
Physical Functioning 24(n=43)86.67 ± 17.959
Role Functioning Baseline(n=51)77.78 ± 23.254
Role Functioning Week 24(n=43)83.72 ± 19.068
Emotional Functioning Baseline(n=51)85.46 ± 17.705
Emotional Functioning Week 24(n=43)92.05 ± 13.357
Cognitive Functioning Baseline(n=51)78.43 ± 20.356
Cognitive Functioning week 24 (n=43)79.84 ± 17.653
Social Functioning Baseline (n=51)85.62 ± 19.154
Social Functioning week 24(n=43)87.60 ± 17.852
Global Health Status/QOL Baseline (n=51)55.72 ± 22.882
Global Health Status/QOL week 24 (n=43)66.47 ± 22.456
Fatigue Baseline(n=51)40.31 ± 23.787
Fatigue week 24 (n=43)28.68 ± 23.412
Nausea and Vomiting baseline (n=51)4.90 ± 13.862
Nausea and Vomiting week 24 (n=43)0.39 ± 2.542
Pain Baseline21.57 ± 21.678
Pain week 24 (n=43)10.08 ± 15.911
Dyspnoea baseline (n=51)22.88 ± 25.377
Dyspnoea Week 24 (n=43)25.58 ± 23.946
Insomnia baseline (n=51)23.53 ± 29.283
Insomnia Week 24 (n=43)15.50 ± 23.400
Appetite Lose baseline (n=51)21.57 ± 27.787
Appetite Lose Week 24 (n=43)9.30 ± 16.786
Constipation baseline (n=51)8.50 ± 20.916
Constipation Week 24 (n=43)8.53 ± 16.416
Diarrhoea baseline (n=51)18.30 ± 24.325
Diarrhoea Week 24 (n=43)12.40 ± 23.029
Financial Difficulties baseline (n=51)15.69 ± 25.257
Financial Difficulties Week 24 (n=43)20.93 ± 30.012

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib—12/51 (23.5%)49/51 (96.1%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventRuxolitinib
AnaemiaBlood and lymphatic system disorders1/51
Disseminated intravascular coagulationBlood and lymphatic system disorders1/51
Cardiac failure congestiveCardiac disorders1/51
Gastrointestinal haemorrhageGastrointestinal disorders1/51
Oesophageal varices haemorrhageGastrointestinal disorders1/51
Multi-organ failureGeneral disorders1/51
Drug-induced liver injuryHepatobiliary disorders1/51
EmpyemaInfections and infestations1/51
SepsisInfections and infestations1/51
Urinary tract infectionInfections and infestations1/51
Most frequent other events
Showing 10 of 22
Most frequent other events
EventRuxolitinib
AnaemiaBlood and lymphatic system disorders32/51
ThrombocytopeniaBlood and lymphatic system disorders15/51
Platelet count decreasedInvestigations12/51
ConstipationGastrointestinal disorders7/51
Hepatic function abnormalHepatobiliary disorders6/51
NasopharyngitisInfections and infestations6/51
PyrexiaGeneral disorders5/51
Electrocardiogram QT prolongedInvestigations5/51
Abdominal painGastrointestinal disorders4/51
DiarrhoeaGastrointestinal disorders4/51

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ruxolitinib
Mean65.7 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Ruxolitinib
Female24
Male27
08

Study locations

29 sites
  • Novartis Investigative Site
    Nagoya-city, Aichi 467-8602, Japan
  • Novartis Investigative Site
    Matsuyama, Ehime 790-8524, Japan
  • Novartis Investigative Site
    Toon-city, Ehime 791-0295, Japan
  • Novartis Investigative Site
    Fukuoka-city, Fukuoka 812-8582, Japan
  • Novartis Investigative Site
    Kurume-city, Fukuoka 830-0011, Japan
  • Novartis Investigative Site
    Maebashi-city, Gunma 371-8511, Japan
  • Novartis Investigative Site
    Sapporo-city, Hokkaido 060-8543, Japan
  • Novartis Investigative Site
    Sapporo-city, Hokkaido 060-8648, Japan
  • Novartis Investigative Site
    Kobe-city, Hyogo 650-0017, Japan
  • Novartis Investigative Site
    Kobe-city, Hyogo 650-0047, Japan
  • Novartis Investigative Site
    Kumamoto City, Kumamoto 860-8556, Japan
  • Novartis Investigative Site
    Kyoto-city, Kyoto 606-8507, Japan
  • Novartis Investigative Site
    Tsu-city, Mie 514-8507, Japan
  • Novartis Investigative Site
    Sendai-city, Miyagi 980-8574, Japan
  • Novartis Investigative Site
    Miyazaki-city, Miyazaki 889-1692, Japan
  • Novartis Investigative Site
    Okayama-city, Okayama 700-8558, Japan
  • Novartis Investigative Site
    Hirakata-city, Osaka 573-1191, Japan
  • Novartis Investigative Site
    OsakaSayama, Osaka 589-8511, Japan
  • Novartis Investigative Site
    Suita-city, Osaka 565-0871, Japan
  • Novartis Investigative Site
    Shimotsuke-city, Tochigi 329-0498, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 113-8431, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 113-8519, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 113-8603, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 113-8677, Japan
  • Novartis Investigative Site
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Novartis Investigative Site
    Shinjuku-ku, Tokyo 162-8666, Japan
  • Novartis Investigative Site
    Chuo-city, Yamanashi 409-3898, Japan
  • Novartis Investigative Site
    Akita, 010-8543, Japan
  • Novartis Investigative Site
    Gifu, 501-1194, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Mar 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2014
First posted
Mar 14, 2014
Start
Apr 2014
Primary completionActual
Mar 2015
CompletionActual
Apr 2015
Results first posted
Jul 11, 2016
Last update
Jul 11, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02087059
Responsible party
Sponsor
First posted
Mar 14, 2014
Start date
Apr 2014
Primary completion
Mar 2015
Completion
Apr 2015
Results posted
Jul 11, 2016
Last update
Jul 11, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion